Theradaptive Wins Additional FDA Breakthrough Designation for Spinal Fusion
Excerpt from the Press Release:
FREDERICK, Md. and BOSTON, Feb. 15, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for its OsteoAdapt SP Spinal Fusion implant indicated for posterolateral spinal fusion to treat degenerative disc disease, spondylolisthesis, or retrolisthesis. This is the second Breakthrough Designation for Theradaptive in spinal fusion.
The Breakthrough Devices Program is a program for select medical devices that provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Under the program, the FDA will provide Theradaptive with priority review and interactive communication regarding device development and clinical trial protocols during the premarket review process.
“This is an important development and the potential for patients is significant. Gaining a Breakthrough Designation from the FDA for posterolateral fusion is a strong indication of the promise of this approach. The expansion into additional indications for spine expands access to a wider potential patient population,” said Dr. Mark Shasti of Inova Loudoun Hospital.
Theradaptive’s regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications. This new technology enables superior outcomes and safety, and greatly improved ease of use.
“This is Theradaptive’s second Breakthrough designation from the FDA in four months and expands our portfolio into the posterolateral fusion approach. This significantly increases the number of patients who can potentially benefit from this game-changing device,” said John Greenbaum, Senior Vice President of Clinical & Regulatory Affairs at Theradaptive.
About Precision Regenerative Implants:
As of 2022 there are no precision regenerative implants available to treat spinal fusion, orthopedic repair, or craniomaxillofacial repair.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?